May 01 2014 Posted: 00:00 IST

NUI Galway’s Regenerative Medicine Institute (REMEDI) and Orbsen Therapeutics will lead a €6 million EU-funded project to develop new diagnostic tests and a cell therapy for the prevention of immunological complications in people receiving corneal transplants.

Corneal transplantation is the most common transplant carried out worldwide, with more than 100,000 procedures per year. It is often the only treatment available to restore sight to people who have lost vision due to diseases of the cornea.

PreviousNext